Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Cancer survivorship sourcebook : basic consumer health information about the physical, educational, emotional, social, and financial needs of cancer patients from diagnosis, through cancer treatment, and beyond, including facts about researching specific types of cancer and learning about clinical …
Table of Contents:; Chapter 1 -- Translation in Immunology: The Role of Translational Biomarkers to Guide Clinical Use of Immunotherapy for Cancer -- Chapter 2 Monoclonal Antibody Therapy -- Chapter 3 Somatic Mutations and Immunotherapy -- Chapter 4 Checkpoint Blockade -- Chapter 5 Myeloid Leukemia…
Table of Contents:; I OVERVIEW -- II DIAGNOSTIC STUDIES -- III NERVOUS SYSTEM INVOLVEMENT OF SYSTEMIC CANCERS -- IV NEUROLOGICAL COMPLICATIONS OF CANCER -- V NEUROLOGICAL COMPLICATIONS OF CANCER THERAPY -- NEUROLOGICAL COMPLICATIONS OF SPECIFIC MALIGNANCIES -- VII NEUROLOGICAL COMPLICATIONS IN LONG…
Table of Contents:; I BASIC PRINCIPLES AND CONSIDERATIONS OF RATIONAL CHEMOTHERAPY AND MOLECULAR TARGETED THERAPY -- BIOLOGIC AND PHARMACOLOGIC BASIS OF CANCER CHEMOTHERAPY --BIOLOGIC BASIS OF MOLECULAR TARGETED THERAPY -- PRINCIPLES OF CANCER IMMUNOTHERAPY -- SYSTEMATIC ASSESSMENT OF THE PATIENT W…
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 6-13 October 2015
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 February 2016
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24-31 May 2016
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 21-28 March 2017
Table of Contents:; 1. HISTORY OF IMMUNOTHERAPY -- 2. PRINCIPLES OF IMMUNOLOGY AND IMMUNOTHERAPY -- 3. CYTOKINES IN IMMUNOTHERAPY -- 4. IMMUNE CHECKPOINT INHIBITORS -- 5. BACILLUS CALMETTE-GUÉRIN - 6. ORAL IMMUNOMODULATORY AGENTS --7. ACTIVE IMMUNITY: VACCINE THERAPY -- 8. PASSIVE/ADOPTIVE IMMUNOTH…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 24 February - 3 March, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 17-24 March, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June, 2009.
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |